Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 974.775 6.775 (0.7%) Market Cap: 107.41 Bil Enterprise Value: 98.84 Bil PE Ratio: 28.80 PB Ratio: 3.98 GF Score: 94/100

Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 04:20PM GMT
Release Date Price: $306.84 (+0.85%)
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Thanks, everybody, for joining us. I'm Terence Flynn, the biopharma analyst here at Goldman. This morning we're very pleased to welcome Regeneron.

And joining us from the company is Jay Markowitz, Senior Vice President of Portfolio Management. Thanks, Jay, for joining us. Really appreciate the time this morning.

Jay S. Markowitz
Regeneron Pharmaceuticals, Inc. - SVP of Portfolio Management

My pleasure.

Questions & Answers

Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Maybe just to kick it off at a high level, I think the one thing is, the company has been front and center in so many of the discussions on drug pricing. EYLEA, you notably haven't taken any price increases since launch. You guys worked with ICER with respect to PRALUENT pricing. DUPI, you guys had engaged payers very early, ahead of the launch.

Maybe just as we think about the forward here, what differentiates your approach, I guess?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot